After working for the Glaxo family of companies for over 20 years, followed by a short period of consulting, I co-founded Respivert Ltd in 2007 to discover novel inhaled anti-inflammatory agents to treat COPD. The company was VC funded and was acquired in 2010. I then I continued to work on the Respivert portfolio of NCEs until leaving to co-found Pulmocide Ltd in 2013. Pulmocide Ltd, once again with VC funding, established 2 discovery programmes: one to treat respiratory syncytial virus and one Aspergillus in the lungs. I am an academically trained biochemist, but and industrially trained pharmacologist.